---
title: "GlucoTrack Restructures Debt Through Equity-Linked Note Exchange"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293975662.md"
description: "GlucoTrack (GCTK) restructured debt by exchanging a portion of a promissory note for equity-linked notes. On July 22, 2026, the company carved out a $900,000 partitioned note, allowing investors to convert debt into common shares based on Nasdaq prices, subject to ownership limits. This move aims to manage its debt profile using private placement exemptions. Meanwhile, TipRanks' AI analyst rates GCTK as an Underperform due to weak financials, cash burn, and delisting risks."
datetime: "2026-07-27T21:00:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293975662.md)
  - [en](https://longbridge.com/en/news/293975662.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293975662.md)
generator: "portal-rs"
---

# GlucoTrack Restructures Debt Through Equity-Linked Note Exchange

The latest announcement is out from GlucoTrack ( (GCTK) ).

On July 22, 2026, Glucotrack, Inc. entered into a new Exchange Agreement with an existing investor to restructure part of a promissory note originally issued on September 12, 2025, and subsequently reduced through prior exchange agreements in April 2026. The parties carved out a new $900,000 partitioned promissory note from the original note, reducing the original note’s outstanding balance by the same amount while leaving its remaining terms in effect.

Under the new arrangement, the investor may periodically exchange all or part of the $900,000 partitioned note into Glucotrack common shares at a price tied to recent Nasdaq closing prices, with exchanges conducted solely by canceling debt rather than paying cash. Issuance of shares is capped by a 9.99% beneficial ownership limitation, and both the partitioned note and resulting exchanges rely on U.S. securities law exemptions for private placements and security-for-security exchanges, highlighting Glucotrack’s continued use of equity-linked financing to manage its debt profile.

**Spark’s Take on GCTK Stock**

According to Spark, TipRanks’ AI Analyst, GCTK is a Underperform.

The score is driven primarily by weak financial performance (no meaningful revenue, recurring losses, and substantial cash burn with negative equity), which implies ongoing funding and dilution risk. Technicals add pressure as the stock trades below all key moving averages with muted momentum. Corporate events provide some offset through clinical/regulatory progress, but near-term uncertainty is elevated due to Nasdaq delisting risk, and valuation support is limited given losses and no dividend.

To see Spark’s full report on GCTK stock,  
 click here. 

**More about GlucoTrack**

Glucotrack, Inc. operates in the medical technology and health-care sector, focusing on devices and solutions related to glucose monitoring and diabetes management. The company’s capital structure involves the use of convertible debt and private placement financing, reflecting an investor base accustomed to structured securities and equity-linked instruments.

**Average Trading Volume:** 6,773,743

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** $2.25M

For a thorough assessment of GCTK stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [GCTK.US](https://longbridge.com/en/quote/GCTK.US.md)

## Related News & Research

- [Glucotrack regains Nasdaq stockholders’ equity compliance, secures continued listing](https://longbridge.com/en/news/296101788.md)
- [GlucoTrack Shareholders Approve Key Governance and Capital Actions](https://longbridge.com/en/news/296385751.md)
- [GlucoTrack unit Lokahi Therapeutics expands ai2 Futures Lab collaboration with University of Georgia](https://longbridge.com/en/news/296614954.md)
- [GlucoTrack holds annual shareholder meeting with 36.1% of shares represented](https://longbridge.com/en/news/296360186.md)
- [GlucoTrack to issue 2,505,513 unregistered shares to White Lion Capital under stock purchase agreement amendment](https://longbridge.com/en/news/295445026.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**